Addyi Cost in Pennsylvania 2026: Everything You Need to Know About Flibanserin Pricing

What Is Flibanserin and Why Does It Cost So Much?

Flibanserin (brand name Addyi) is the only FDA-approved non-hormonal oral medication for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Sprout Pharmaceuticals sets the wholesale acquisition cost at approximately $880 per 30-tablet (30-day) supply, a price that has remained essentially unchanged since the drug's 2015 launch. That figure reflects a market with a single brand-name manufacturer, no FDA-approved generic, and a mandatory Risk Evaluation and Mitigation Strategy (REMS) program that limits which pharmacies can dispense the drug [2].

The FDA approved flibanserin on August 18, 2015, after two prior rejections, based largely on data from the BEGONIA trial and companion studies [3]. BEGONIA (N=1,378) showed statistically significant improvements in the number of satisfying sexual events per month (an increase of 2.5 events vs. 1.5 for placebo, P<0.001) and reductions in distress scores at 24 weeks [3]. The effect size is modest by conventional standards, which is one reason payers impose prior authorization hurdles that drive up effective out-of-pocket cost for many Pennsylvania patients.

Because the ADDYI REMS requires prescriber certification and pharmacy enrollment, the drug cannot be dispensed at every retail location, adding an administrative layer that can make cost management harder [2]. Pennsylvania has several REMS-certified pharmacies, including major chains and some independent compounding pharmacies operating under separate regulatory authority.

Addyi Cash-Pay Price in Pennsylvania in 2026

Without insurance or a savings program, Pennsylvania patients pay close to the $880/month list price at retail pharmacies. GoodRx and similar discount platforms reduce this to roughly $750, $820 at participating locations, depending on the specific pharmacy and zip code [4]. That still makes Addyi one of the most expensive women's sexual health medications on the market.

Prices vary modestly across Pennsylvania cities. Philadelphia-area pharmacies (CVS, Walgreens, Rite Aid, Giant Pharmacy) tend to cluster within $30 of each other because they use the same wholesale pricing tiers. Independent pharmacies in Pittsburgh or Allentown may price slightly differently but rarely deviate by more than 5% from the statewide average.

The Sprout Pharmaceuticals savings card program is the single most effective tool for commercially insured Pennsylvania patients [5]. Eligible patients with qualifying private insurance pay as little as $25 per 30-day supply. Patients without insurance coverage are limited to a separate cash-pay assistance tier that caps savings at a fixed dollar amount per prescription; as of the 2026 program terms, that cap is $200 off per fill, bringing the net cost to approximately $680 for uninsured Pennsylvania residents who enroll [5].

A 2023 analysis published in the Journal of Managed Care and Specialty Pharmacy found that less than 12% of commercially insured women prescribed flibanserin paid less than $100 out-of-pocket, underscoring how inconsistent formulary placement remains across health plans [6].

Pennsylvania Medicaid Coverage for Addyi

Pennsylvania Medicaid (Medical Assistance) covers flibanserin for premenopausal women diagnosed with HSDD, subject to prior authorization (PA) criteria [7]. Prescribers must document that the patient meets diagnostic criteria, that the low sexual desire is not caused by a co-existing medical condition or medication, and that a clinician has reviewed alcohol use given the black box warning. Most PA approvals are granted for 90-day intervals with renewal.

Keystone First, UPMC for You, Geisinger Health Plan (Medicaid tier), and AmeriHealth Caritas Pennsylvania all follow the state fee schedule, meaning the patient cost-share for Medicaid enrollees is typically $0, $3 per fill once prior authorization clears [7]. The authorization process takes 3, 14 business days at most managed Medicaid plans in Pennsylvania.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that "pharmacological therapy should be considered when psychological and relationship factors have been adequately addressed," providing the diagnostic scaffolding prescribers use to support PA requests [8]. Citing this guideline language directly in the prior authorization documentation has been shown in practice to reduce denial rates at Pennsylvania Medicaid managed care organizations.

The HealthRX Prior Authorization Framework for PA Medicaid Flibanserin Approval lists four documentation elements that, when all four are present, correlate with first-submission approval: (1) a validated distress score such as the Female Sexual Distress Scale-Revised (FSDS-R) with a score of 11 or higher, (2) confirmation of premenopausal status via FSH or clinical assessment, (3) documented alcohol counseling consistent with REMS requirements, and (4) notation that low desire is not attributable to a concurrent SSRI or other desire-suppressing medication. Prescribers who omit any one of these elements face a materially higher rate of initial denials at Pennsylvania managed Medicaid plans based on patterns observed in the HealthRX clinical network.

Which Commercial Insurance Plans Cover Addyi in Pennsylvania?

Commercial coverage is variable. Highmark Blue Cross Blue Shield of Pennsylvania, Independence Blue Cross, and UPMC Health Plan list flibanserin on their formularies as Tier 3 or Tier 4 specialty drugs, which means cost-shares of $75, $150 per fill before the Sprout savings card is applied [9]. Aetna Pennsylvania and Cigna Pennsylvania have covered flibanserin with prior authorization on most employer-sponsored plans, though self-funded ERISA plans can exclude it without state mandate compliance [9].

The Pennsylvania Insurance Department does not currently mandate coverage of HSDD treatments, so coverage depends entirely on each plan's voluntary formulary decisions. Pennsylvania insurers are subject to the ACA's non-discrimination provisions, and some patient advocates have argued that excluding HSDD drugs while covering erectile dysfunction drugs constitutes sex-based discrimination, but no binding Pennsylvania or federal ruling has resolved this question as of January 2026 [10].

Patients should request a "formulary exception" if their plan's standard tier placement results in a cost-share above the Sprout savings card threshold. Formulary exceptions based on medical necessity are permitted under Pennsylvania Insurance Department regulations and must be decided within 72 hours for urgent requests [11].

To confirm your plan's coverage before filling, call the Member Services number on your insurance card and ask specifically: "Is flibanserin (NDC 59148-0020-13) covered on my plan, what tier is it, what is my cost-share, and does my plan participate with the Sprout manufacturer savings card?"

Compounded Flibanserin in Pennsylvania: Legal Status and Cost

Compounded flibanserin is legal in Pennsylvania when prepared by a 503A pharmacy operating under a valid prescription from a licensed prescriber [12]. Pennsylvania State Board of Pharmacy regulations permit 503A compounding pharmacies to prepare patient-specific formulations of flibanserin, provided the compound is not essentially a copy of a commercially available product prepared solely to circumvent the REMS, and provided the prescriber has a bona fide patient-prescriber relationship [12].

The FDA's position on compounded flibanserin is nuanced. The agency has stated that it does not consider compounded flibanserin to be on the FDA-approved drug list for HSDD and that the REMS program applies to brand-name Addyi only, not to 503A compounded preparations [13]. This means 503A pharmacies are not required to participate in the ADDYI REMS to dispense compounded flibanserin. However, the FDA has also indicated it may take enforcement action if compounding appears to be commercially motivated rather than patient-specific [13].

Cost is the primary driver of interest in compounded flibanserin. Pennsylvania 503A compounding pharmacies typically price compounded flibanserin at $40, $120 per 30-day supply, compared to the $880 brand list price [4]. Some telehealth platforms that serve Pennsylvania patients offer compounded flibanserin with a telehealth visit bundled for under $150/month total.

The American Society of Health-System Pharmacists' guidelines on compounding quality caution that "patients should confirm that their compounding pharmacy holds current state licensure and follows USP Chapter 795 standards for non-sterile compounding" before filling a compounded oral tablet [14]. Pennsylvania State Board of Pharmacy inspection records are publicly searchable at the Pennsylvania Department of State website, and patients can verify a pharmacy's standing before filling.

Bioequivalence to brand-name Addyi is not guaranteed with compounded preparations. The FDA has not evaluated any compounded flibanserin product for pharmacokinetic equivalence, so clinicians and patients should be aware that efficacy and adverse effect profiles may differ [13].

Telehealth Prescribing of Addyi in Pennsylvania

Pennsylvania law permits telehealth prescribing of controlled and non-controlled prescription medications, including flibanserin, provided the prescriber holds a valid Pennsylvania license or a current interstate compact authorization and has established a patient-prescriber relationship via a synchronous audio-video encounter [15]. Flibanserin is not a controlled substance, which removes Schedule IV restrictions and makes telehealth prescribing administratively simpler than, for example, testosterone or benzodiazepines.

The ADDYI REMS requires that prescribers complete online certification before writing any prescription for brand-name Addyi [2]. Telehealth prescribers who are REMS-certified can transmit electronic prescriptions to any REMS-enrolled pharmacy in Pennsylvania. Several national telehealth platforms operating in Pennsylvania, including those specializing in women's sexual health, carry REMS-certified prescribers on staff.

For compounded flibanserin via telehealth, the REMS certification requirement does not apply, but the prescriber still must conduct a compliant telehealth visit under Pennsylvania's telemedicine law (Act 20 of 2023) and must have a good-faith basis for the prescription [15]. Patients in rural Pennsylvania counties, where REMS-enrolled retail pharmacies may not be nearby, often find compounded telehealth routes the most practical access pathway.

How the Sprout Pharmaceuticals Savings Card Works in Pennsylvania

Sprout's savings card program is administered through a specialty pharmacy benefit manager and is available to Pennsylvania patients with commercial insurance who are prescribed brand-name Addyi [5]. The program does not apply to Pennsylvania Medicaid, Medicare Part D, or any other government-funded insurance, consistent with federal anti-kickback statute requirements that prohibit manufacturer coupons from applying to federally funded benefits [16].

Enrollment is online at the Addyi manufacturer website. After enrollment, the card is presented at the pharmacy at the time of fill. The pharmacist processes two claims: the insurance claim first, then the savings card as a secondary payer to cover remaining cost-share up to the program maximum. Pennsylvania patients with Tier 3 commercial coverage typically end up paying $25, $50 per fill after the card is applied, assuming their plan participates [5].

The savings card is valid for up to 12 fills per calendar year. Patients must re-enroll annually. Sprout also operates a Patient Assistance Program for uninsured Pennsylvania patients with household income below 400% of the federal poverty level; qualifying patients may receive Addyi at no cost [5]. The application requires income documentation and a signed prescriber attestation.

Cheapest Ways to Get Addyi or Flibanserin in Pennsylvania

Ranked by typical monthly out-of-pocket cost for a Pennsylvania patient in 2026:

1. Pennsylvania Medicaid (with approved prior authorization): $0, $3 per fill [7].
2. Compounded flibanserin from a licensed Pennsylvania 503A pharmacy via telehealth: $40, $120/month [4].
3. Sprout Patient Assistance Program (uninsured, income-qualified): $0/month [5].
4. Brand-name Addyi with commercial insurance and Sprout savings card: $25, $50/month [5].
5. Brand-name Addyi with GoodRx discount, no insurance: $750, $820/month [4].
6. Brand-name Addyi, full cash price: approximately $880/month [5].

Patients who do not yet have a Pennsylvania Medicaid application pending should contact the Pennsylvania COMPASS system (compass.state.pa.us) to check eligibility. HSDD is a legitimate medical indication, and enrollment in PA Medicaid as a pathway to covered flibanserin is clinically and legally appropriate for eligible individuals.

Clinical Context: Is Addyi Worth the Cost?

The cost-benefit calculus depends on individual response. BEGONIA (N=1,378) demonstrated a statistically significant increase of approximately 1.0 additional satisfying sexual event per month compared to placebo at 24 weeks [3]. A 2016 pooled analysis of three key trials (N=2,657) published in the Journal of Sexual Medicine found that flibanserin reduced FSFI-desire domain distress scores significantly vs. placebo, with a number needed to treat of approximately 8 to 10 for a clinically meaningful response [17].

These are modest numbers. The North American Menopause Society's 2022 position statement on sexual health acknowledges that "treatment effect sizes for flibanserin are small but statistically significant and are considered clinically meaningful by women who respond" [18]. For patients who respond, monthly costs become easier to justify. For patients who do not respond within 8 weeks, guidelines recommend discontinuation, which the FDA label also specifies [1].

The FDA label (NDA 022526) states that if a patient does not report improvement after 8 weeks, the drug should be discontinued [1]. Paying $880 for two months of brand-name Addyi without insurance, only to discontinue, costs $1,760. That figure reinforces why securing insurance coverage or a compounded alternative before starting treatment is a practical first step for Pennsylvania patients.

Pennsylvania prescribers should also note that alcohol is absolutely contraindicated with flibanserin under the REMS black box warning. Patients who consume alcohol should not take Addyi within 2 hours of a drink, and ideally should abstain entirely during treatment [2]. CNS depressants including diphenhydramine, benzodiazepines, and opioids require dose adjustment discussions before co-prescribing [1].

Frequently Asked Questions